HSP90AA1 and cancer: The inhibition of such crucial function affects many normal proteins, results in high toxicity.115 Hsp90 inhibitor SNX-5422 developed by Pfizer terminated clinical phase 1 trial in 2011 due to ocular toxicity.116 Therefore, researchers believe that targeting Hsp90 and its molecular chaperones is a new direction for the cancer treatment study.117,118